Astellas Launches Irritable Bowel Syndrome Drug Irribow
This article was originally published in PharmAsia News
Executive Summary
Astellas launched Irribow (ramosetron) Oct. 7 in Japan, a drug indicated to treat diarrhea-predominant irritable bowel syndrome in males. A serotonin 5-HT3 receptor antagonist, Irribow is the first serotonin receptor antagonist treatment in Japan. (Click here for more - Japanese language
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.